Biopharma, the White House And Getting Drug Pricing ‘Off The Table’

 
• By Cathy Kelly

Industry balks at President Trump’s latest effort to force biopharma to negotiate a drug pricing solution, but investors may be pushing for concessions that could head off more onerous policies supported by a Biden White House. 

White house in Washington DC (USA)
The White House Meeting That Wasn't

More from Pricing Debate

More from Market Access